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Abstract
Background: It is well established that COMT is a strong candidate gene for substance use disorder and
schizophrenia. Recently we identified two SNPs in COMT (rs4680 and rs165774) that are associated with
schizophrenia in an Australian cohort. Individuals with schizophrenia were more than twice as likely to carry the
GG genotype compared to the AA genotype for both the rs165774 and rs4680 SNPs. Association of both rs4680
and rs165774 with substance dependence, a common comorbidity of schizophrenia has not been investigated.
Methods: To determine whether COMT is important in substance dependence, rs165774 and rs4680 were
genotyped and haplotyped in patients with nicotine, alcohol and opiate dependence.
Results: The rs165774 SNP was associated with alcohol dependence. However, it was not associated with nicotine
or opiate dependence. Individuals with alcohol dependence were more than twice as likely to carry the GG or AG
genotypes compared to the AA genotype, indicating a dominant mode of inheritance. The rs4680 SNP showed a
weak association with alcohol dependence at the allele level that did not reach significance at the genotype level
but it was not associated with nicotine or opiate dependence. Analysis of rs165774/rs4680 haplotypes also revealed
association with alcohol dependence with the G/G haplotype being almost 1.5 times more common in alcohol-
dependent cases.
Conclusions: Our study provides further support for the importance of the COMT in alcohol dependence in
addition to schizophrenia. It is possible that the rs165774 SNP, in combination with rs4680, results in a common
molecular variant of COMT that contributes to schizophrenia and alcohol dependence susceptibility. This is
potentially important for future studies of comorbidity. As our participant numbers are limited our observations
should be viewed with caution until they are independently replicated.
Background
Catechol-O-methyl transferase (COMT) is an enzyme
involved in the degradation of dopamine [1] and is
encoded by the COMT g e n e .T h i sl i e si nar e g i o nt h a t
has been strongly implicated in schizophrenia [2-4]. The
COMT gene is located on chromosome 22q11 and asso-
ciation studies have identified a number of polymorph-
isms that are associated with schizophrenia [5-11]. One
of the more interesting polymorphisms is rs4680 that
encodes either valine or methionine at amino acid posi-
tion 158, with the substitution shown to alter COMT
enzyme activity [12]. The only other non-synonymous
polymorphism in COMT that has been found to be
associated with schizophrenia is rs6267. This alanine/
serine substitution also alters COMT enzyme activity
but has only been identified in Asian populations
[13,14].
Along with schizophrenia, studies have also identified
COMT associations with a range of psychiatric condi-
tions. A haplotype including the rs4680 polymorphism
is associated with risk for several anxiety disorders and
major depression [15] and the rs4680 polymorphism has
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any medium, provided the original work is properly cited.been associated with panic disorder [16] and early onset
major depression in a large European study [17].
Another European study found that COMT variation
could predict onset of depressive episodes following
exposure to stressful life events [18]. The rs4680 poly-
morphism has been studied in addictive behaviours and
found to contribute significantly to the development of
late-onset alcohol dependence [19]. A Finnish study of
896 males found rs4680 to not only contribute signifi-
cantly to alcohol intake in alcoholics but also in the
general male population [20]. Smoking cessation and
association with the rs4680 polymorphism was found in
a large study from the Netherlands [21]. As well as nico-
tine and alcohol dependence, opiate dependence has
also been studied for the rs4680 polymorphism. An
association with opiate dependence and rs4680 was
observed in Hispanic women but did not hold up after
correction for multiple testing [22]. However there have
been conflicting studies for COMT including a study
that did not observe association with alcohol depen-
dence or nicotine dependence [23]. Genome-wide asso-
ciation studies of nicotine and alcohol dependence have
not found association with COMT to date [24-27].
Previously we confirmed that rs4680 is associated with
s c h i z o p h r e n i ai na nA u s t r a lian population but we have
identified stronger association with schizophrenia with a
novel COMT SNP, rs165774 [28]. Since psychotic disor-
ders are often comorbid with alcohol and other sub-
stance dependence [29,30], we genotyped the two
COMT polymorphisms in alcohol, nicotine and opiate
dependence.
Methods
Participants
Controls
The control group consisted of 250 unrelated Cauca-
sians (102 female and 148 male) with a mean age of
36.8 years (s.d. ± 12.8 years). The control group con-
sisted of volunteers from the general public, hospital
nursing and medical staff, and university staff and stu-
dents. Formal screening for psychological disorders was
not undertaken in the control population. As such the
controls represent an unselected control group and may
include individuals with substance dependence. To
minimise population stratification bias, both control and
clinical subjects were recruited in the Brisbane region (a
city of approximately 2 million inhabitants on the East
Coast of Australia) and all were of British or European
descent (ascertained by subject self-reporting).
Opiate Dependence
A total of 120 unrelated Caucasian participants (50
female and 70 male) diagnosed as opiate-dependent
were recruited for this study. All subjects were assessed
using a checklist of specific criteria by a consultant
psychiatrist or physician experienced in drug and alco-
hol dependence and met DSM-IV criteria for opiate
dependence. All were being assessed for naltrexone
treatment as outpatients in a large public hospital detox-
ification unit in Brisbane, Australia. Participants had a
mean age of 30.0 years of age (s.d. ± 7.9 years). Approxi-
mately half of the participants were being managed on
methadone prior to detoxification (47.2%) while the
other half were on heroin (52.8%). Those on methadone
had a mean dose of 48.1 milligrams (s.d. 30.5), with a
range between 10-165 milligrams. The mean age of
onset of heroin use was 22.4 years of age (s.d. 5.14),
with a range between 15-43 years. Mean number of par-
ticipant-reported detoxifications prior to this occasion
was 3.5 (s.d. 3.3), with a range between 0-16 detoxifica-
tions. Cannabis was the most common concurrently
used illicit substance reported by participants prior to
treatment (52.5% reported use), followed by ampheta-
mines (14.9% reported use). Opiate-dependent subjects
were excluded from the study if they had an organic
brain syndrome, psychosis or any other condition that
would affect their ability to provide informed consent.
Alcohol Dependence
A total of 231 unrelated Caucasian (74 female and 157
male) alcohol-dependent subjects were recruited from
large public hospitals in Brisbane, Australia. All subjects
were assessed using a checklist of specific criteria by a
clinical psychologist experienced in drug and alcohol
dependence and met DSM-IV criteria of alcohol depen-
dence. Participants had a mean age of 40.74 years (s.d. ±
10.3 years). All were inpatients and represented a spec-
trum of severity with a significant proportion (n =6 5 )
of these patients being diagnosed with two or more
alcohol related medical conditions such as pancreatitis,
cirrhosis, hepatitis or peripheral neuropathy. Alcohol-
dependent patients were excluded from the study if they
had an organic brain syndrome, psychosis, or any other
condition that would affect their ability to provide
informed consent.
Nicotine Dependence
A total of 147 (68 male, 79 female) unrelated Caucasians
with a mean age of 43.3 (s.d. ± 11.1 years) were
recruited for smoking reduction with a view to eventual
cessation through hospital and media advertisements.
All subjects were assessed using a checklist of specific
criteria by a consultant psychiatrist or physician experi-
enced in drug and alcohol dependence and met DSM-
IV criteria of nicotine dependence. All subjects were
outpatients. Participant inclusion criteria included 18
years of age or older and smoking for at least three
years and being generally healthy despite currently
smoking 15 cigarettes or more per day. All were moti-
vated to reduce smoking and had the goal of eventual
cessation. However, all participants had at least one
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vious 24 months. One hundred and thirty nine of the
participants were administered the Fagerstrom test for
Nicotine Dependence [31].
Ethics approval was obtained from all institutions
involved and each participant from the control, opiate
dependence, alcohol dependence and nicotine depen-
dence groups gave written informed consent.
Genotyping
Oragene kits were used to extract DNA from saliva
samples. Samples were genotyped using a homogeneous
MassEXTEND (hME) Sequenom assay [32] performed
by the Australian Genome Research Facility. The hME
assay is based on the annealing of an oligonucleotide
primer (hME primer) adjacent to the SNP of interest.
The addition of a DNA polymerase along with a mixture
of terminator nucleotides allows extension of the hME
primer through the polymorphic site and generates
allele-specific extension products, each having a unique
molecular mass. The resultant masses of the extension
products are then analysed by matrix-assisted laser des-
orption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) and a genotype is assigned in real
time. The hME assay was performed in multiplex with
up to 36 reactions in a single well.
Primers sequences for rs165774 are as follows: PCR
Primer 1: ACGTTGGATGGCCCTACCTAGCCAGG-
CAT; PCR Primer 2: ACGTTGGATGTCCCA-
GAAACTGGACACTGC; Extension Primer: cgct
CCTCGTGCTCCTAGTC. Primers sequences for rs4680
are as follows: PCR Primer 1: ACGTTGGATGTTTTC-
CAGGTCTGACAACGG; PCR Primer 2: ACGTTG-
GATGACCCAGCGGATGGTGGATTT; Extension
Primer: tcacGCACACCTTGTCCTTCA.
The genotyping fail rate was 3.75% for rs165774 and
6.92% for rs4680 for all included patients. The genotyp-
ing of several other SNPs were independently verified by
other methods such as real-time PCR with a concor-
d a n c er a t eo f9 6 . 6 %( t h eCOMT SNPs were not inde-
pendently verified). Genotypes were determined by
investigators blinded for clinical diagnoses.
Statistical Analysis
AP e a r s o n ’s chi-squared test was performed to identify
statistical associations between alleles and genotype and
substance dependence status. Odds ratios (OR) were
also calculated. Tests were performed on both genotype
and allele data. Statistical tests were performed using
the COMPARE2 program from the WinPepi suite of
epidemiology programs [33] and SPSS version 18.
Hardy-Weinberg equilibrium (HWE) was computed
using Utility Programs for Analysis of Genetic Linkage
[34]. The analysis of genotypes under a recessive model
involved pooling the low-risk homozygotes and the het-
erozygotes and comparing frequencies with the high-risk
homozygotes, i.e. OR > 1. Correction for multiple test-
ing was conducted using the Benjamini-Hochberg
method [35]. Linkage disequilibrium and haplotype esti-
mations were calculated using JLIN version 1.6.0 [36].
Results
Two COMT SNPs (rs165774 and rs4680) which we had
previously found to be associated with schizophrenia
were genotyped in 250 controls, 147 nicotine-dependent
subjects, 120 opiate-dependent subjects and 231 alco-
hol-dependent subjects to investigate their association
with substance dependence. In addition to our pre-
viously reported association with schizophrenia,
rs165774 was found to be associated with alcohol
dependence at the allele level after correction for multi-
p l et e s t i n g .T h e r ew a sn oa ssociation with opiate or
nicotine dependence (Table 1). For the two groups
(nicotine and opiate dependence) that did not show
association with rs165774, we did not have sufficient
power (< 0.80) to detect association with our sample
size using retrospective power calculations for a case-
control study in syntax SPSS version 18 because the
odds ratios were so low (nicotine OR = 1.24 and opiate
OR = 1.28). In fact a sample size ranging from 2000-
3000 cases and controls would be required to show any
significance for rs165774 with opiate or nicotine depen-
dence with odds ratios of this size.
At the genotype level, rs165774 was still associated
with alcohol dependence (Table 2). Individuals with
alcohol dependence were more than twice as likely to
carry the GG or AG genotype compared to the AA gen-
otype. The rs165774 SNP was found to follow a domi-
nant mode of inheritance for alcohol dependence when
genotypes were pooled (p = 0.006, OR 2.24, 95% CI 1.2
to 4.3).
In addition to our previously reported association with
schizophrenia, rs4680 was only marginally associated
with alcohol dependence at the allele level (Table 3) but
was not significant with opiate or nicotine dependence.
Table 1 Allele Association of COMT SNP rs165774
Sample Allele
frequency
c
2 p-
value*
Odds
Ratio
95% CI
GA
Controls 304 176
Nicotine
dependence
199 93 1.856 0.173 1.24 0.91-
1.69
Opiate dependence 161 73 2.072 0.150 1.28 0.91-
1.78
Alcohol
dependence
319 133 5.509 0.019 1.39 1.05-
1.83
* p-value determined by Pearson’s chi-squared test (DF = 1)
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dence did not hold up at the genotype level (p = 0.135)
and it did not survive correction for multiple testing.
For the two groups (nicotine and opiate dependence)
that did not show association with rs4680, the odds
ratios were even lower (nicotine OR = 1.03 and opiate
OR = 1.24) requiring a sample size ranging from 2000-
200000 cases and controls.
Analysis of combined addictive disorders (alcohol,
nicotine and opiate dependence) revealed no association
at the genotype level (p = 0.18) or allele level for rs4680
(p = 0.114). Combined addictive disorders were asso-
ciated with rs165774 at the allele level (p =0 . 0 2 0 )b u t
not at the genotype level (p = 0.062).
In addition, the nicotine-dependent group genotype
was tested for an association with the Fagerstrom Nico-
tine Dependence Test (FNDT). Analysis of variance
revealed no significant associations between FNDT and
genotype (rs165774: p=0.135, F=2.032; rs4680: p =
0.520, F = 0.656).
Linkage disequilibrium (LD) analysis was performed
on all groups for the rs4680 and rs165774 SNPs. Strong
LD was found between the two SNPs in all groups. Con-
trols: D’ =0 . 9 3 ,r
2 =0 . 3 7 .N i c o t i n e :D ’ =1 . 0 ,r
2 =0 . 3 7 .
Opiate: D’ =0 . 9 0 ,r
2 =0 . 3 5 .A l c o h o l :D ’ = 0.98, r
2 =
0.41. Haplotype analysis of rs165774 and rs4680 was
performed in all groups and only reached statistical sig-
nificance in the alcohol-dependent group (Table 4).
When all substance dependence groups were analysed
together as a single phenotype, the haplotypes did not
show association.
Respective genotype frequencies indicated that both
polymorphisms were in HWE in both case and control
samples, with the exception of rs165774 in the nicotine
group (c
2 =5 . 6 ,p=0.02), although this SNP did not
show association with the nicotine dependence group.
Discussion
Two SNPs in COMT previously identified as being asso-
ciated with schizophrenia [28] were examined for their
association with alcohol, nicotine and opiate depen-
dence. Evidence suggests that a common molecular axis
involving the dopamine pathway exists for multiple psy-
chiatric disorders. One SNP in COMT rs4680 (Val 158
Met) has received considerable scientific attention as it
influences the availability of COMT and subsequently
the efficiency of extracellular dopamine degradation.
Homozygosity for 158 Met leads to a 3-4 fold reduction
in enzymatic activity compared with homozygosity for
158 Val [37,38]. Since COMT plays a crucial role in the
metabolism of dopamine it is likely that it contributes to
the etiology of alcohol dependence. Alcohol-induced
euphoria is associated with rapid release of dopamine in
limbic areas and a study has shown that subjects with
the 158 Met polymorphism have low dopamine inactiva-
tion and are more vulnerable to alcohol dependence
[19]. It is well known that psychotic disorders are fre-
quently comorbid with alcohol and other substance
dependence [29,30] but it is not possible to tell whether
this is because these disorders have a common
Table 2 Genotype Association of COMT SNP rs165774
Sample Genotype Counts p-value*
AA (%) AG (%) GG (%)
control 39 (16.25) 98 (40.83) 103 (42.92)
Nicotine dependence 21 (14.38) 51 (34.93) 74 (50.69) 0.330
Odds ratio 1 0.966 1.334 0.205
†
p-value 1.000 0.700
Opiate dependence 13 (11.11) 47 (40.17) 57 (48.72) 0.363
Odds ratio 1 1.439 1.660 0.172
†
p-value 0.626 0.300
Alcohol dependence 18 (7.96) 97 (42.92) 111(49.12) 0.022
Odds ratio 1 2.146 2.336 0.023
†
p-value 0.029 0.012
* p-value determined by Pearson’s c
2 test (DF = 2)
† p-value determined using the extended Mantel-Haenszel test for trend (DF =
1)
Table 3 Allele Association of COMT SNP rs4680
Sample Allele
frequency
c
2 p-
value*
Odds
Ratio
95% CI
GA
Controls 194 244
Nicotine
dependence
126 154 0.035 0.852 1.03 0.76-
1.39
Opiate dependence 110 112 1.639 0.200 1.24 0.89-
1.71
Alcohol
dependence
231 223 3.880 0.049 1.30 1.00-
1.69
* p-value determined by Pearson’s chi-squared test (DF = 1)
Table 4 Haplotype analysis of COMT rs4680 and
rs165774 polymorphisms in patients with alcohol
dependence
Haplotype
rs4680/
rs165774
Controls
c
(%)
Alcohol
c
(%)
Odds Ratio
a
(P)
c
2b P
A/A 147 (34.5) 126
(28.4)
1 3.794 0.051
A/G 93 (21.8) 89 (20.0) 1.116 (1.000) 0.419 0.517
G/A 5 (1.2) 1 (0.2) 0.233 (0.392) 3099 0.078
G/G 181 (42.5) 228
(51.4)
1.470 (0.042) 6.866 0.009
TOTAL 426 444 9.656 0.022
a Odds ratio with respect to rs4680 A/rs165774 A haplotype which is more
commonly associated with a normal phenotype
b Likelihood ratio c
2 test comparing haplotype frequency between groups
when all other haplotypes were pooled (DF = 1, and DF = 3 for total c
2)
c Haplotypes frequencies were estimated using JLIN version 1.6.0
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leads to substance abuse via an as yet unidentified
mechanism.
Association studies of rs4680 have produced varied
results and it may play a role in susceptibility to a range
of psychiatric conditions. Another possible candidate
regarding risk is rs165774 that we have previously
shown to be associated with schizophrenia and is in
strong linkage disequilibrium with rs4680 [28]. Most
studies of COMT have focused on rs4680 and a stronger
candidate polymorphism is yet to be identified. Analysis
of rs165774 revealed associations with alcohol depen-
dence at both the allele and genotype levels. Although
rs4680 was associated with alcohol dependence at the
allele level, the association was not convincing and did
n o th o l du pa tt h eg e n o t y p el e v e l .N i c o t i n ea n do p i a t e
dependence were not associated with rs4680 or
rs165774 in our study but association cannot be ruled
out as we only analysed a limited number of cases
(Tables 1 and 3).
T h eo n l yo t h e rs t u d yb e s i d e sour schizophrenia study
[28] that has found association with a neurological/psy-
chiatric condition and rs165774 is a Chinese study
examining mental retardation in a Chinese Han popula-
tion [39]. The rs165774 SNP has not been studied in
genome-wide association studies.
Conclusions
This study identified a polymorphism in COMT that
possibly plays a role in psychiatric liability for schizo-
phrenia and alcohol dependence. The rs165774 poly-
morphism may affect COMT enzyme activity and
therefore dopamine inactivation resulting in vulnerabil-
ity to substance dependence. The rs165774 SNP dis-
played stronger association with alcohol dependence
than rs4680 but it is in tight LD with the non-synon-
ymous SNP rs4680. A limitation of our study is that
controls were not screened for psychiatric conditions
including substance dependence. However not screening
controls is unlikely to bias results as screening would be
likely to strengthen the associations observed between
cases and controls. Another limitation was that no SCID
(Structured Clinical Interview for DSM Disorders) was
performed on patients. However, all participants met
DSM-IV criteria. We did not adjust our P-values for
multiple testing as the validity of this technique is con-
troversial and has been shown to increase type II errors,
making important differences non-significant [40].
Therefore, our significant association must be seen as
exploratory and further replication is required. For the
opiate and nicotine-dependent groups that did not show
significance with rs165774 or rs4680, replication in an
independent study is required with a larger sample size.
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